Search for a trial

A First-In-Human study of 89ZR-DFO-REGN5054 (anti-CD8) Positron Emission Tomography in patients with solid malignancies treated with cemiplimab

The primary objective:To determine the safety and tolerability of 89Zr*DFO*REGN5054 alone and in combination with cemiplimab.Secondary ObjectivesFor Part A:• To characterize the radioactivity pharmacokinetic (PK) profile of 89Zr DFO REGN5054• To…